Landmark Trials in Heart Failure—DELIVER and EMPEROR-Preserved—Will SGLT2 Inhibitors Succeed in Heart Failure with Preserved Ejection Fraction?
Saturday, June 26, at 8:30 a.m. ET
Q&A with Muthiah Vaduganathan, MD, MPH
What is your presentation about?
Don’t miss out on this session featuring a global panel of colleagues highlighting the latest learnings from recently completed and ongoing trials of sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failure and chronic kidney disease.
What makes this topic important in 2021?
The scope of application of SGLT2 inhibitors has exploded in recent years; their use in heart failure and chronic kidney disease are particularly important given the high prevalence of these conditions and excess burden of related clinical events in the community.
Which subset of attendees shouldn’t miss this presentation?
I will be sharing insights regarding the design features and recent adaptations of the DELIVER and EMPEROR-Preserved trials, the two largest clinical trials ever conducted in heart failure with preserved ejection fraction (HFpEF). I will offer my predictions regarding the potential final results of these now blinded, but soon-to-be released trials.